确定囊性纤维化患者40项嗅觉识别测试的最小临床重要差异
本研究汇总三项前瞻性多中心观察研究数据,纳入122例≥12岁囊性纤维化合并慢性鼻窦炎患者,旨在确定40项嗅觉识别测试(SIT)在囊性纤维化患者中的最小临床重要差异(MCID)。采用四种基于分布的MCID计算方法,得出合并MCID阈值为3.1分(95%CI:2.1-4.1)。
要点
- 囊性纤维化患者SIT的MCID合并阈值为3.1分(95%CI:2.1-4.1)。
- ETI治疗后SIT评分总体稳定,6个月时轻微下降1.4分(p=0.02)。
- ESS术后早期随访SIT评分平均提高3.1-4.5分,但未达统计学显著性。
核心结论
- 囊性纤维化患者40项SIT的合并MCID阈值为3.1分(95%CI:2.1-4.1),为嗅觉评估提供临床可解释的界限。
研究设计与样本
- 汇总三项前瞻性多中心观察性研究数据,纳入122例≥12岁确诊囊性纤维化合并慢性鼻窦炎患者。
- 99例提供随访SIT评分(79例接受ETI治疗,20例接受ESS)。
- 采用四种基于分布的方法计算MCID:测量标准误(SEM)、最小可检测变化(MDC=1.96×SEM)、0.5×基线标准差、0.5×变化值标准差。
主要发现
- ETI治疗后SIT评分保持稳定,6个月时出现小幅但统计学显著的下降(-1.4分,p=0.02)。
- ESS术后早期随访SIT评分平均提高3.1-4.5分,但未达到统计学显著性。
- 基于分布的MCID估计范围为2至4分,合并阈值为3.1(95%CI:2.1-4.1)。
关键数值与推荐
- 囊性纤维化患者40项SIT的MCID阈值为3.1分(95%CI:2.1-4.1)。
临床怎么用
- 该囊性纤维化特异性SIT阈值可用于临床解读嗅觉变化,辅助评估治疗效果。
- 研究强调开发疾病特异性MCID对指导临床照护和研究的重要性。
局限性
- ESS亚组样本量较小(20例),其结果未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40-item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF-specific minimal clinically important difference (MCID) has not been established. This study aimed to determine the SIT MCID in PwCF treated with elexacaftor/tezacaftor/ivacaftor (ETI) and/or endoscopic sinus surgery (ESS). METHODS: Data from three prospective, multi-institutional observational studies were pooled. Participants were ≥12 years old with confirmed CF and CRS who completed SIT at baseline and ≥1 follow-up (3, 6, 9, 12, or 24 months). Distribution-based MCIDs were calculated using four methods: standard error of measurement (SEM), minimal detectable change (MDC = 1.96 × SEM), 0.5 × baseline standard deviation (SD), and 0.5 × SD of change scores (ΔSD). RESULTS: A total of 122 participants were enrolled (mean age 32.9 years, 54% female). Of these, 99 contributed follow-up SIT scores (79 ETI, 20 ESS). SIT scores remained stable with ETI, with a small but statistically significant decline at 6 months (-1.4, p = 0.02). ESS was associated with mean gains of 3.1-4.5 points at early follow-up, though these did not reach significance. Pooled distribution-based MCID estimates ranged from 2 to 4 points, with an overall threshold of 3.1 (95% CI: 2.1-4.1). CONCLUSIONS: This CF-specific SIT threshold provides a clinically interpretable cut-off for assessing olfaction. These findings establish a foundation for future work and highlight the importance of developing disease-specific MCIDs to guide clinical care and research.
引用
- Oh E, Miller JE, Lee MJ, et al. Determining the Minimal Clinically Important Difference of the 40-Item Smell Identification Test in People With Cystic Fibrosis. Int Forum Allergy Rhinol. 2026. PMID: 41830161. doi:10.1002/alr.70136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。